Watts, Eleanor LAppleby, Paul NPerez-Cornago, AuroraBueno-de-Mesquita, H BasChan, June MChen, ChuCohn, Barbara ACook, Michael BFlicker, LeonFreedman, Neal DGiles, Graham GGiovannucci, EdwardGislefoss, Randi EHankey, Graeme JKaaks, RudolfKnekt, PaulKolonel, Laurence NKubo, TatsuhikoLe Marchand, LoïcLuben, Robert NLuostarinen, TapioMännistö, SatuMetter, E JeffreyMikami, KazuyaMilne, Roger LOzasa, KotaroPlatz, Elizabeth AQuirós, J RamónRissanen, HarriSawada, NorieStampfer, MeirStanczyk, Frank ZStattin, PärTamakoshi, AkikoTangen, Catherine MThompson, Ian MTsilidis, Konstantinos KTsugane, ShoichiroUrsin, GiskeVatten, LarsWeiss, Noel SYeap, Bu BAllen, Naomi EKey, Timothy JTravis, Ruth C2018-08-202018-08-202018-08-01Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. 2018 Eur. Urol.1873-75603007739910.1016/j.eururo.2018.07.024http://hdl.handle.net/10029/622136Experimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.enArchived with thanks to European urologyArticleEur Urol 2018; 74(5):585-94